Loading data for CGEM — first visit, this takes a few seconds.

Alerta

Cullinan Therapeutics Inc... (CGEM)

NasdaqGS: CGEM · Precio en tiempo real · USD

22.85

-0.10 (-0.44%)

Al cierre: Aug 26, 2026, 3:59 PM

23.10

+1.07%

Fuera de horario: 5:36 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

-0.44% (1D)

Precio de compra	16.49
Capitalización de mercado	1.4B
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-208.34M
	-0.02
	-3.11
	n/a
	-8.43
P/B (TTM)	4.57
P/S (TTM)	n/a
Fecha de resultados	May 14, 2021

Precio de venta	28.88
Volumen	683,330
Volumen medio (20D)	953,741
Abierto	22.66
Anterior Cerrar	22.95
Rango del día	22.42 - 23.19
Rango de 52 semanas	5.68 - 23.19
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de CGEM

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in ...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Jan 8, 2021

Empleados 109

Bolsa de Valores NasdaqGS

Símbolo bursátil CGEM

Sitio web https://cullinantherapeutics.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Cullinan Therapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -219.88M, un aumento de 31.36%.

Estados financieros

Sorpresa de resultados

Cullinan Therapeutics ha publicado sus resultados trimestrales en Aug 6, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.
EPS de -0.81 supera las estimaciones en 0.04, con 24.30% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Cullinan Therapeutics Inc. publique sus resultados el May 14, 2021, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · BioPharma Dive

New Taiho, Cullinan data heats up lung cancer drug battle

The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

2 semanas hace · Simply Wall St.

The Bull Case For Cullinan Therapeutics (CGEM) Could Change Following FDA-Backed Phase 2 CLN-049 Trial

Cullinan Therapeutics reported second-quarter 2026 results with a net loss of US$53.7 million and basic loss per share of US$0.81, both lower than a year earlier, alongside six-month net loss of US$10...

3 semanas hace · Simply Wall St.

Cullinan Therapeutics (CGEM) Advances CLN 049 After FDA Feedback, Is The Upside Already Priced In?

Cullinan Therapeutics (CGEM) drew investor attention after receiving positive U.S. Food and Drug Administration feedback on its End of Phase 1 meeting for CLN-049 in acute myeloid leukemia. See our la...

1 mes hace · Exec Edge

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clon...

2 meses hace · Simply Wall St.

Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes

Earlier in June 2026, Cullinan Therapeutics reported updated Phase 1 data showing CLN-978 and velinotamig produced strong clinical responses and favorable safety in treatment-refractory rheumatoid art...

Página 1 de 2

Cullinan Therapeutics Inc... (CGEM)